Keep an Eye on BioMarin, Amgen, Merck, and AstraZeneca Today
These four stocks -- BioMarin, Amgen, Merck, and AstraZeneca -- are worth paying attention to today. Let's take a look at the top headlines for these companies this morning.
The Simplest Biotech Growth Portfolio Ever
Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.
Celgene's Revlimid Faces a Tough Sell
In cost-conscious countries, even existing therapies face an uphill battle in winning approval for new indications. With new data behind it, Celgene hopes it can overcome cost concerns to win approval for Revlimid as a first-line treatment.
Has Myeloma Met Its Match in Amgen's Kyprolis?
Amgen's high profile acquisition of Onyx Pharmaceuticals gave it Kyprolis, an existing multiple myeloma treatment with an opportunity to expand beyond its current indication.
A Shifting Paradigm in Heart Disease Could Affect These Drugmakers
Amgen, Regeneron, and Sanofi are among the companies impacted by a change to the cardiologist's mindset.